La Madonnina Clinic
La Madonnina Clinic
Italia, Milano
| Italia | Turchia | Austria | |
| Trattamento sintomatico | - | da $300 | da $700 |
Revisionato medicalmente da
Fahad MawloodBookimed non aggiunge costi extra ai prezzi dei trattamenti di Malattia policistica renale. Le tariffe provengono dai listini ufficiali delle cliniche. Pagherai direttamente in clinica al tuo arrivo nel paese.
Bookimed si impegna per la tua sicurezza. Lavoriamo solo con strutture che mantengono elevati standard internazionali nei trattamenti di Malattia policistica renale e hanno le licenze necessarie per servire pazienti internazionali in tutto il mondo.
Bookimed offre assistenza esperta gratuita. Un coordinatore medico personale ti supporta prima, durante e dopo il trattamento, risolvendo qualsiasi problema. Non sarai mai solo nel tuo percorso di trattamento per Malattia policistica renale.
Professor Fabio Carmignani is a specialist in andrology, urology, and prostatic biopsy under MRI guidance. He has been the Director of the Urology Department at Policlinico San Donato Research Hospital in Milan since 2007 and has over 10,000 surgeries to his credit. He has a medical degree from the University of Milan and is the President of the Foundation of the Italian Society of Urology. He has written over 100 research materials in urologic surgery and is a member of the American Urological Association and the Italian Society of Urology, Minimal Invasive Therapy.
Dr. Alessandro Calarco is a skilled urologist with expertise in minimally invasive and endourological procedures. He performs percutaneous lithotripsy, ureterorenoscopy, tumor ablation, and advanced reconstructive surgeries. Dr. Calarco has received international recognition for his clinical work and research. He completed advanced training in Sweden and the UK.
Dr. Calarco graduated with top honors from Università Cattolica del Sacro Cuore in Rome. He completed his Urology specialization and earned a PhD in Oncological Urology at the same university. His research focuses on prostate cancer biomarkers and exosomes. He has also helped develop clinical protocols for hormone-refractory prostate cancer.
He serves as National Head of Urology for SPIGC and is a member of the European Board of Urology. Dr. Calarco holds an international patent for a device that improves percutaneous nephrolithotripsy. He has published extensively and received several awards for surgical innovation and education.